JNJ-2113 口服疗法在中度至重度斑块状银屑病中显示出积极的 2b 期结果，证明了新治疗选择的潜力。 JNJ-2113 oral therapy shows positive Phase 2b results in moderate-to-severe plaque psoriasis, demonstrating potential for new treatment option.
研究性口服疗法 JNJ-2113 在针对中重度斑块型银屑病患者的 2b 期研究中显示出积极的结果，实现了所有主要和次要终点和改善。 Investigational oral therapy JNJ-2113 demonstrated positive results in a Phase 2b study for patients with moderate-to-severe plaque psoriasis, achieving all primary and secondary endpoints and improvements. 这些研究结果发表在《新英格兰医学杂志》上，强调了 JNJ-2113 作为这种疾病新治疗选择的潜力。 These findings were published in the New England Journal of Medicine and highlight the potential of JNJ-2113 as a new treatment option for this condition.